// App-Quantinova.ai

AB0526 (2021) : SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

Researchers

Presenter

  • C. T. Ritchlin

Principal Investigators

  • P. J. Mease

  • W. H. Boehncke

  • J. Tesser

  • E. Schiopu

  • S. D. Chakravarty

  • A. Kollmeier

  • E. C. Hsia

  • X. L. Xu

  • M. Shawi

  • Y. Jiang

  • S. Sheng

  • J. F. Merola

  • I. McInnes

  • A. Deodhar

Medical Centers

  • University of Rochester, Allergy/Immunology and Rheumatology, Rochester, United States of America

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • Geneva University Hospitals, Geneva, Switzerland

  • Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, United States of America

  • Michigan Medicine Rheumatology Clinic, Rheumatology & Internal Medicine, Ann Arbor, United States of America

  • Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • University of Pennsylvania School of Medicine, Immunology, Philadelphia, United States of America

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Brigham And Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology, Boston, United States of America

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

Locations

  • United States

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Body mass index

  • Albumin/creatinine

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved